2015 Annual Meeting On Demand: Saturday Sessions

You can earn up to 14 AMA PRA Category 1 Credit(s)™. This activity has also been designated by the ABAI for 8 MOC Part II Self-Assessment credits.

This collection covers general sessions from Saturday's program. This includes plenaries, symposia, and, for the first time, several workshops have been included. The sessions listed below are included in this package.

  • Biologics in Practice:  Unique Opportunity for Allergist Expertise
  • The Sky is Not Falling: Flourishing Despite Tectonic Shifts to U.S. Health Care
  • Altering the Natural History of Allergic Diseases With Immunotherapy
  • W8 Severe Asthma
  • W9 Food Allergies
  • W11 Atopic Dermatitis
  • W14 Drug Reactions


Release Date: 12/15/2015
Expiration Date: 12/14/2018


The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The American College of Allergy, Asthma & Immunology (ACAAI) designates this enduring material for a maximum of 14 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Learning Objectives

• Discuss phenotypes and endotypes in the context of the patient with severe asthma 
• Describe the relative advantages and disadvantages associated with various asthma pharmacotherapies, particularly biologics 
• Discuss the side effect profiles of the various new therapies and how to go about handling such complications
• Examine reasons for entering healthcare as a profession and discuss how these factors relate to personal experience ·        

• Demonstrate how healthcare work and personality characteristics interact to facilitate a natural progression toward burnout and compassion fatigue 
• Build a resilient practice utilizing the resilience that can be built into a system of care
• Recognize the similarities and differences in logistics, efficacy, and safety of SLIT and SCIT for inhalant allergies 

• Discuss results of recent food allergy immunotherapy clinical trials 
• Discuss likely future strategies for performing immunotherapy, including using adjuvants, biologicals, and peptides
• Describe how severe asthmatics are uniquely different and review the evaluation/assessment of these patients, comparing pediatric and adult and develop a treatment plan for patients with severe asthma
• Diagnose the correct type of food allergy based on symptoms and utilize diagnostic modalities, including the most recent IgE tests and apply knowledge of the natural history of food allergy to the management of patients and advise patients regarding the utilization of food allergen labeling
• Identify common and uncommon causes of severe eczema and describe the rationale for an extended therapeutic ladder for patients refractory to standard treatments with special emphasis on compliance


Additional information

Mark Boguniewicz, MD, FACAAI -- Consultant/Advisor: Celgene, Regeneron; Supported/Contracted Research: Anacor

Peter A. Lio, MD -- Consultant/Advisor: Anacor, Galderma, Johnson & Johnson, Pierre Fabre, Valeant 

J. Andrew Bird, MD, FACAAI -- Speaker: Nutrica; Supported/Contracted Research: Aimmune Therapeutics, DBV Technologies

Julie Wang, MD, FACAAI -- Consultant/Advisor: JDP Therapeutics, Merck 

Leonard B. Bacharier, MD, FACAAI -- Consultant/Advisor: Boehringer Ingelheim, DBV Technologies, GlaxoSmithKline, Meda,Teva; Speaker: AstraZeneca, Novartis 

Reynold A. Panettieri, Jr., MD -- Consultant/Advisor: AstraZeneca, Johnson & Johnson; Supported/Contracted Research: Gilead, Johnson & Johnson, Merck, Roche, Sanofi

Myron J. Zitt, MD, FACAAI -- Consultant/Advisor: Integrity, Sanofi, McNeil, Boehringer Ingelheim; Speaker: Integrity, Mylan, Meda, Boston Scientific

Chitra Dinakar, MD, FACAAI -- Consultant/Advisor: Aerocrine; Supported/Contracted Research: GlaxoSmithKline, Merck, Teva

Harold S. Nelson, MD, FACAAI -- Consultant/Advisor: AstraZeneca, Circassia, Merck, Pearl Therapeutics; Supported/Contracted Research: Circassia

Stanley M. Fineman, MD, MBA, FACAAI -- Speaker: AstraZeneca, Genentech, Meda, Merck, Mylan; Supported/Contracted Research: Genentech, Meda

Rohit K. Katial, MD, FACAAI -- Consultant/Advisor: AstraZeneca, GlaxoSmithKline, Meda, Teva; Speaker: GlaxoSmithKline, Meda

James L. Sublett, MD, FACAAI -- Consultant/Advisor: AllergyZone, Boston Scientific, Greer; Speaker: Genentech, GlaxoSmithKline, Meda, Merck, Sunovion, Teva; Supported/Contracted Research: Array BioPharma, AstraZeneca, Boehringer Ingelheim, Forest, Mylan, Sanofi

Larry Borish, MD, FACAAI -- Consultant/Advisor: Allakos, Knopp, Novartis, PluriStem

Thomas B. Casale, MD, FACAAI -- Consultant/Advisor: AstraZeneca, Genentech, Novartis, Sanofi, Teva

David A. Khan, MD, FACAAI -- Speaker: Baxter, Genentech

The following have no financial relationships to disclose:

Bryan L. Martin, DO, FACAAI 

Mark T. O'Hollaren, MD, FACAAI

Kenneth Yeager, PhD

Kari C. Nadeau, MD, PhD

Course summary
Available credit: 
  • 14.00 AMA PRA Category 1 Credit™
  • 14.00 Attendance
  • 8.00 MOC
Course opens: 
Course expires: 

Available Credit

  • 14.00 AMA PRA Category 1 Credit™
  • 14.00 Attendance
  • 8.00 MOC
Please login or create an account to take this course.